"" Ralph Moss—Cancer Consultant: REMARKABLE NEW BLOOD TEST FOR CANCER

Thursday, January 14, 2016

REMARKABLE NEW BLOOD TEST FOR CANCER

Once in a rare while a diagnostic test comes along of urgent importance to cancer patients. ONCOblot is such a test.

I learned about this from a scientific book, ECTO-NOX Proteins: Growth, Cancer and Aging (Springer 2013). This eye-opening book offered a detailed and well-organized record of five decades of research by the husband-and-wife team of D. James Morré, PhD and Dorothy Morré, PhD, mainly conducted as professors at Purdue University in West Lafayette, Indiana. James Morré, the Dow Professor of Medicinal Chemistry, was the founding director of Purdue’s cancer research center.

In this groundbreaking book, the Morrés explain the global significance of a class of proteins called “ECTO-NOX,” which is commonly abbreviated ENOX. This protein acts on the surface or exterior of cells (from the ancient Greek ectos, “outside”). ENOX2 is found in cancer of many kinds. It and related ENOXes are crucially involved in cell growth, biological time keeping, cancer, aging and even viral infections. 

These ENOX proteins are unique in a number of ways. For instance, their expression depends on a particular biological clock, or circadian rhythm, that varies from 22 to 26 minutes. They carry out two separate physiological functions in rapid succession.

Particularly thought provoking is the Morrés’ discussions of ENOX2, which has resulted in the revolutionary ONCOblot blood test for cancer. ENOX2 is specific for cancer and plays an indispensable role by allowing an immature cancer cell to enlarge to a normal size. The Morrés spent decades perfecting a practical test for ENOX 2, which is now called ONCOblot. This test can differentiate among 26 different types of cancer. According to the www.oncoblotlabs.com Web site, the test can detect tumors as small as 2 mm in diameter, which represents about 2 million cells. It can find tumors years before conventional scans. This makes it much more sensitive than a typical scan. If cancers can be detected at this early stage, and distinguished as to tissue of origin, then this alone represents a huge advance in the cancer field. It allows for early detection and medical intervention to eliminate small tumors before they become increasingly difficult to treat. 

I hope the reader now senses the enormous potential of this line of research, the fruit of more than 50 years of determined work at Purdue and elsewhere. James Morré himself has published around 400 PubMed-indexed scientific papers. If we now truly have a way to detect very early cancers, differentiate their tissue of origin, and then treat and eliminate them in their preclinical stages, I believe that the Morrés have gone a long way to solving the cancer puzzle! This proposition of course requires further testing. But, at this point, the burden of proof shifts from these remarkable scientists to the large and well-funded government and private agencies, which have the capacity to carry out large-scale testing. The fact that they have not done so is both puzzling and frustrating. One hopes this is not another instance of the determined suppression of a generic and non-toxic approach in the interest of entrenched medical interests.

In sum, since the 1960s, the Purdue University scientists James and Dorothy Morré have produced an amazing body of scientific work, which they have summarized with admirable clarity in a 500-page text and in hundreds of journal articles. It offers a detailed explanation of how and why the detection of ENOX2 provides an accurate diagnosis for many different kinds of cancer.

To access the ONCOblot diagnostic test for 26 different types of cancer: